Short Course of Weekly Low-Dose Intravenous Pulse Cyclophosphamide in the Treatment of Lupus Nephritis: A Preliminary Study

Abstract

We review our experience with low-dose intravenous pulse cyclophosphamide as treatment of biopsy-proven lupus nephritis. Seventeen patients were treated with 2-4 (mostly 3) weekly low-dose intravenous pulses of cyclophosphamide (500 mg) and moderate doses of prednisolone (0.5mg/kg/day), followed by an oral immunosuppressive drug (either azathioprine or cyclophosphamide). As compared with the classical monthly high-dose cyclophosphamide regimen, this weekly low-dose regimen induced neutropenia in one patient only. The incidence of herpes zoster was very low (6 %). At the end of the follow-up period (15 ± 8 months), two patients required chronic ambulatory peritoneal dialysis. The 14 patients that could be evaluated improved their mean serum albumin from 30 ± 7 to 37.5 ±7 g/l (mean ± SD; P < 0.01) and their mean serum creatinine fell from 125 ± 119 to 101 ± 66 μmol/l (not significant). Mean DNA binding dropped from 71 ± 29 to 26 ± 27 % (P < 0.001) and mean complement fraction C4 levels increased from 14 ± 8 to 28 ± 18 mg/dl (P < 0.05). The mean daily prednisolone dose was dramatically reduced from 26 ± 8 to 10 ± 4 mg (P < 0.001). Although this preliminary and retrospective study clearly needs validation with a larger cohort followed for a longer period, it seems that a treatment combining moderate doses of steroids and 3-4 weekly low-dose intravenous pulses of cyclophosphamide, followed by oral immunosuppression, is well tolerated and beneficial — at least in the short term — for most patients with severe lupus nephritis.

Keywords

Cyclophosphamide Systemic lupus erythematosus Lupus nephritis

Get full access to this article

View all access options for this article.

References

Balow JE , Austin HA III , Tsokos GC , Antonovych TT , Steinberg AD , Klippel JH Lupus nephritis. NIH conference. Ann Int Med 1987; 106: 79-94.

Donadio JV , Holley KE , Wagoner RD , Ferguson RH , McDuffie FC. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972; 77: 829-35.

Decker JL , Klippel JH , Plotz PH , Steinberg AD Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med 1975; 83: 606-15.

Balow JE , Austin HA III, Muenz LR et al. The effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 491-5.

Austin HA III, Klippel JH , Balow Je et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.

McCune WJ , Golbus J. , Zeldes W. , Bohlke P. , Dunne R. , Fox DA Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423-31.

Klippel'JH , Austin HA III , Balow JE et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am 1987; 13:47-56.

Balow JE Lupus nephritis: pathogenesis, course and management. Adv Exp Med Biol 1989; 252: 3-15.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

10.

Churg J. , Sobin LH Lupus nephritis. In: Renal Disease. Tokyo : Igaku-Shoin, 1982: 127-49.

11.

Bryant BM , Jarman M. , Ford HT et al. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulfonate sodium (Mesnum) in patients with advanced carcinoma. Lancet 1980; ii: 657-9.

12.

Cupps TR , Edgar LC , Fauci AS Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453-7.

13.

Ozer H. Jr, Cowens JW , Colvin M. , Nussbaum-Blumenson A. , Sheedy D. In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. J Exp Med 1982; 155: 276-90.

14.

Hurd E. Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis Rheum 1973; 16: 88-91.

15.

Clements PJ , Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Sem Arthritis Rheum 1986; 15: 231-54.

16.

Austin HA III, Muenz LR , Joyce KM , Antonovych TT , Balow JE Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25:689-95.